Drug Repurposing Market Size, Industry Trends And Future Outlook By 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Drug Repurposing Market Size Analysis

Global Drug Repurposing Market Introduction
By Method
1. Introduction
  1. Method By Value
2. Drug Centric
  1. By Value
3. Disease Centric
  1. By Value
4. Target Centric
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Autoimmune Diseases
  1. By Value
4. Rare Diseases
  1. By Value
5. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical & Biotechnology Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Academic and Research Institutions
  1. By Value

North America Market Analysis

Introduction
By Method
1. Introduction
  1. Method By Value
2. Drug Centric
  1. By Value
3. Disease Centric
  1. By Value
4. Target Centric
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Autoimmune Diseases
  1. By Value
4. Rare Diseases
  1. By Value
5. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical & Biotechnology Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Academic and Research Institutions
  1. By Value
U.S.
1. By Method
  1. Introduction
    1. Method By Value
  2. Drug Centric
    1. By Value
  3. Disease Centric
    1. By Value
  4. Target Centric
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Autoimmune Diseases
    1. By Value
  4. Rare Diseases
    1. By Value
  5. Others
    1. By Value
3. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical & Biotechnology Companies
    1. By Value
  3. Contract Research Organizations
    1. By Value
  4. Academic and Research Institutions
    1. By Value
Canada

Europe Market Analysis

Introduction
By Method
1. Introduction
  1. Method By Value
2. Drug Centric
  1. By Value
3. Disease Centric
  1. By Value
4. Target Centric
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Autoimmune Diseases
  1. By Value
4. Rare Diseases
  1. By Value
5. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical & Biotechnology Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Academic and Research Institutions
  1. By Value
U.K.
1. By Method
  1. Introduction
    1. Method By Value
  2. Drug Centric
    1. By Value
  3. Disease Centric
    1. By Value
  4. Target Centric
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Autoimmune Diseases
    1. By Value
  4. Rare Diseases
    1. By Value
  5. Others
    1. By Value
3. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical & Biotechnology Companies
    1. By Value
  3. Contract Research Organizations
    1. By Value
  4. Academic and Research Institutions
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Method
1. Introduction
  1. Method By Value
2. Drug Centric
  1. By Value
3. Disease Centric
  1. By Value
4. Target Centric
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Autoimmune Diseases
  1. By Value
4. Rare Diseases
  1. By Value
5. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical & Biotechnology Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Academic and Research Institutions
  1. By Value
China
1. By Method
  1. Introduction
    1. Method By Value
  2. Drug Centric
    1. By Value
  3. Disease Centric
    1. By Value
  4. Target Centric
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Autoimmune Diseases
    1. By Value
  4. Rare Diseases
    1. By Value
  5. Others
    1. By Value
3. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical & Biotechnology Companies
    1. By Value
  3. Contract Research Organizations
    1. By Value
  4. Academic and Research Institutions
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Method
1. Introduction
  1. Method By Value
2. Drug Centric
  1. By Value
3. Disease Centric
  1. By Value
4. Target Centric
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Autoimmune Diseases
  1. By Value
4. Rare Diseases
  1. By Value
5. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical & Biotechnology Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Academic and Research Institutions
  1. By Value
UAE
1. By Method
  1. Introduction
    1. Method By Value
  2. Drug Centric
    1. By Value
  3. Disease Centric
    1. By Value
  4. Target Centric
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Autoimmune Diseases
    1. By Value
  4. Rare Diseases
    1. By Value
  5. Others
    1. By Value
3. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical & Biotechnology Companies
    1. By Value
  3. Contract Research Organizations
    1. By Value
  4. Academic and Research Institutions
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Method
1. Introduction
  1. Method By Value
2. Drug Centric
  1. By Value
3. Disease Centric
  1. By Value
4. Target Centric
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Autoimmune Diseases
  1. By Value
4. Rare Diseases
  1. By Value
5. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical & Biotechnology Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Academic and Research Institutions
  1. By Value
Brazil
1. By Method
  1. Introduction
    1. Method By Value
  2. Drug Centric
    1. By Value
  3. Disease Centric
    1. By Value
  4. Target Centric
    1. By Value
2. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Autoimmune Diseases
    1. By Value
  4. Rare Diseases
    1. By Value
  5. Others
    1. By Value
3. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical & Biotechnology Companies
    1. By Value
  3. Contract Research Organizations
    1. By Value
  4. Academic and Research Institutions
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Drug Repurposing Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

BioXcel Therapeutics Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Rejuvenate Biomed NV.
SOM Biotech, S.L.
Biogen Inc
Bristol-Myers Squibb Company
Every Cure
NovaLead Pharma Pvt. Ltd.
AstraZeneca PLC
Hoffmann-La Roche AG
Pfizer Inc.
Johnson & Johnson Services, Inc.
LifeArc
Takeda Pharmaceutical Company Limited
Sanofi S.A.
GSK plc.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment